Eupraxia Pharmaceuticals (EPRX) Share-based Compensation (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Share-based Compensation data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 50.85% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 111.28% increase from a year earlier, with the FY2025 full-year figure at $8.8 million, up 171.64% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.3 million, down from $5.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for EPRX reached as high as $5.7 million in Q4 2025 and fell as low as $213130.0 in Q1 2024.
• Historically, Share-based Compensation has averaged $1.2 million across 4 years, with a median of $507246.0 in 2024.
• Across the five-year window, Share-based Compensation slumped 32.86% in 2024 and jumped 600.7% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $309844.0 in 2023, then jumped by 231.83% to $1.0 million in 2024, then soared by 454.32% to $5.7 million in 2025, then plunged by 60.47% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.3 million in Q1 2026, $5.7 million in Q4 2025, and $446106.0 in Q3 2025.